Last updated on October 2018

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

Brief description of study

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Clinical Study Identifier: NCT03024996

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: WO39210 ...

Banner MD Anderson Cancer Center
Gilbert, AZ United States
  Connect »